Cellular therapies: Day by day, all the way

Area of Science:

• Biomedical Science
• Regenerative Medicine
• Immunotherapy

Background:

• Cellular therapies, termed "living drugs," represent a paradigm shift in treating diseases.
• Advances in gene editing and cellular reprogramming fuel numerous clinical trials for previously incurable conditions.
• Adoptive T cell immunotherapies and CAR T-cell therapies have significantly advanced the field.

Purpose of the Study:

• To review the current landscape of cellular therapy research.
• To highlight immunotherapy and CAR T-cell treatments.
• To compile global regulatory and marketing information for cellular therapeutics.

Main Methods:

• Literature review of current research trends in cellular therapy.
• Analysis of clinical trial data and investment trends.
• Compilation of regulatory frameworks and marketing strategies for cell-based products.

Main Results:

• Thousands of clinical trials are active, with significant investment in cell-based therapies.
• Regulatory bodies are increasing licensing activities under GxP rules.
• Despite progress, limited success compared to conventional drugs, with unresolved cost and ethical issues.

Conclusions:

• Cellular therapy holds immense potential but faces significant hurdles in standardization, cost-effectiveness, and commercialization.
• Further research and regulatory harmonization are crucial for realizing the full therapeutic potential of living drugs.
• Addressing scientific, translational, commercial, and ethical challenges is paramount for widespread adoption.